The ‘Abilify’ injection will be adopted in the domestic market

A long-acting injection product that has attracted the schizophrenia field will be adopted.

According to the industry concerned on the 10^th, Korea Otsuka Pharmaceuticals is getting ready to turn in a new drug application to get an approval for the schizophrenia treatment ‘Abilify (aripiprazole)’ as a LAI type. Considering general procedures, it is expected to launch in 2016.

Typically, oral m...